Pfizer Enters Innovent Biologics Global Collaboration for up to $10.5 Billion for 12 Innovative Cancer Medicines

Ropes & Gray advised Pfizer in entering a strategic global licensing and collaboration agreement with China-based Innovent Biologics for the research and development of 12 innovative cancer medicines worth up to $10.5 billion. The transaction announced on May 28 includes licensing, co-development and co-commercialization opportunities across a diverse portfolio of antibody-drug conjugates (ADCs) with differentiated payloads and multi-specific antibodies with differentiated immune-engaging designs. The transaction is expected to close in the third quarter of 2026.

The agreement to advance a broad pipeline of cancer therapies spans a portfolio comprising eight Innovent-originated early-stage programs and four Pfizer-proposed discovery programs. The companies will co-develop and share costs for select programs as they advance through clinical development.

Under the three-part licensing and commercialization structure, first Pfizer will receive an exclusive global license for four programs and fund global development costs. Second, Pfizer retains exclusivity for four programs only outside of Greater China with responsibility for the majority of development costs. Third, Pfizer and Innovent will co-develop four programs globally, with both parties sharing development expenses, jointly bringing products to market in the U.S. and Europe, sharing resulting profits, and Innovent retaining rights to these programs within Greater China.

Under the agreement, Innovent will receive a $650 million upfront payment and is eligible for up to $9.85 billion in development, regulatory, and commercial milestone payments. Additionally, Innovent will receive royalties on sales of each licensing product if approved. For the co-developed, co-commercialized programs, the two companies will share the profits in the U.S. and Europe.

The Ropes & Gray team was led by IP transactions partner Geoffrey Lin and counsel Jimmy Chen and included tax partner David Saltzman.